Last reviewed · How we verify
Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy (DCECRT)
Definitive chemoradiotherapy with cisplatin with cisplatin plus 5-fluorouracil is the standard in Western countries in esophagus cancer.But in China because of its toxic reaction, most of patients stop the halfway.Because low toxicity, Capecitabine is widely used in the chemotherapy of esophageal cancer. The purpose of this experiment was to study the different cycle on capecitabine with chemotherapy for esophageal cancer chemoradiation effect.We are prepared to within 2 years study recruited 200 patients with esophageal cancer.The primary endpoint is overall survival and the secondary endpoints include progression-free survival, response rate,pathologic complete response rate and adverse events.
Details
| Lead sponsor | The First Affiliated Hospital of Henan University of Science and Technology |
|---|---|
| Phase | Phase 3 |
| Status | UNKNOWN |
| Enrolment | 200 |
| Start date | 2014-10 |
| Completion | 2019-12 |
Conditions
- Stage III Esophageal Squamous Cell Carcinoma
- Stage II Esophageal Squamous Cell Carcinoma
Interventions
- Capecitabine(Aibin)
- radiotherapy
Primary outcomes
- overall survival, OS — 2 years
Countries
China